ReviewInfectious disorders drug targets2025
Therapeutic Potential of Emodin: A Mini-Review of Its Anti-Biofilm and Antimicrobial Effects.
Review in Infectious disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In vitro nano‑emodin-associated exosome‑mediated aPDT against Acinetobacter baumannii.AMB Express · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resistance of biofilms to antimicrobial agents presents numerous challenges. The formation of biofilms leads to enhanced resistance to adverse environmental conditions, as well as to antimicrobial agents. Natural compounds have been of interest as potential therapeutic agents. Emodin, a natural anthraquinone compound, has recently attracted attention for its potential as a broad-spectrum antimicrobial agent. This ability could potentially help combat biofilm-associated infections and enhance the effectiveness of antimicrobial therapies. This review was carried out to evaluate the effects of emodin on microbial biofilms, determine its effectiveness in inhibiting and reducing biofilm formation, eradicate biofilms, and examine its antimicrobial effects. Our study shows that the use of emodin as an additional therapeutic agent in combating microbial biofilms holds considerable promise. As researchers continue to investigate how emodin interacts with microbial biofilms, there is excitement about the potential applications of this natural compound in addressing biofilm-related issues. However, it is suggested to pay more attention to evaluating the effects of emodin on microbial biofilms in future studies.
Indexed as
Identifiers
39710928What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.